For someone whose main problem is repeated hot flashes, Veozah presents a focused question: what evidence supports this particular medicine, and what work accompanies its use? The brand identifies an oral fezolinetant tablet. It does not identify a clinic, a completed prescription or an arrangement for the blood tests associated with treatment.
We reviewed the current US prescribing information on September 29, 2026. This article concerns the medicine record, not a firsthand trial or a recommendation to request it. Its February 2026 revision retains the boxed liver warning. Understanding the benefit and that warning together is more useful than treating a nonhormonal description as a general assurance of safety.
Start with the specific symptom and product
The Veozah prescribing information identifies fezolinetant as an NK3 receptor antagonist for moderate to severe vasomotor symptoms due to menopause. The labeled form is a 45 mg tablet. That strength describes the reviewed product; it is not an instruction for a reader to begin treatment.
The indication does not cover every complaint that can accompany midlife. A reduction in hot flashes cannot be presumed to treat a separate mood disorder, vaginal symptoms or every source of disturbed sleep. Our medicine-family explanation helps identify the intended target before comparing offers that use the same broad menopause language.
Read the placebo comparison before reading a ranking
The clinical-studies section describes two phase 3 trials whose primary efficacy comparison covered the first twelve weeks. Participants had frequent moderate to severe vasomotor symptoms, and the studies assessed changes in frequency and severity at specified visits. The labeled findings favor Veozah over placebo for those outcomes.
That is evidence about a defined population, product and comparator. It is not a trial demonstrating that this medicine beats every alternative. The Lynkuet review concerns a different product with a different record. Reading the two labels side by side does not create a head-to-head study, and this review supplies no numerical clinical ranking.
The boxed warning changes the practical conversation
The current boxed warning reports hepatotoxicity after marketing and requires liver laboratory assessment before and during treatment. Postmarketing information can identify problems that the original trials did not fully characterize. It should remain visible beside the efficacy findings rather than be treated as an unrelated administrative requirement.
The safety record also distinguishes laboratory elevations observed in trials from reported liver injury after approval. Those are not interchangeable measures of an individual's future risk. Our liver-monitoring guide explains the responsibility for orders, results and communication. This review does not interpret laboratory numbers or provide a personal testing calendar.
Restrictions require the actual medical and medicine history
The label's contraindications include known cirrhosis, severe renal impairment or end-stage renal disease, and concurrent use of CYP1A2 inhibitors. The interaction section includes weak, moderate and strong inhibitors; a reader should not assume that only a medicine described as a strong inhibitor matters.
These restrictions need a prescriber and pharmacist who know the actual diagnoses and complete medication list. A satisfactory result on one test does not settle every restriction, and choosing a hormone-free medicine does not bypass the review. Include nonprescription products and medicines prescribed elsewhere when asking how the team will reconcile the proposed treatment with existing care.
New symptoms can require action before routine follow-up
The patient safety instructions say to stop Veozah immediately and seek medical attention, including liver testing, for symptoms suggesting liver injury. Listed symptoms include unusual new fatigue, reduced appetite, nausea or vomiting, itching, yellow skin or eyes, pale stools, dark urine or abdominal pain. A planned future test is not a reason to postpone that instruction.
These are the product's safety directions, not a home diagnosis or permission to restart after symptoms improve. The visit-goals guide can help frame the practical question: which contact handles an urgent problem, and how are the prescriber and outside laboratory informed? Ordinary membership messaging should not be assumed to provide urgent assessment.
A product label cannot quote the whole care arrangement
The official medicine record establishes product information, not a personal pharmacy price, insurance authorization or appointment fee. We did not verify a completed order, selected pharmacy stock or an all-inclusive treatment package. A written estimate would need to distinguish the prescription, clinician visits and required laboratory services.
The Hello Alpha review illustrates why an advertised menopause service is a separate subject from a named product. Its general service description should not be read as verified Veozah supply. Wherever care is sought, obtain confirmation of the proposed medicine and who remains responsible for the associated safety work before interpreting a monthly figure as the total cost.
Keep the benefit question open during continuing care
The Veozah label includes adverse reactions and evidence limits as well as its indication. For example, the geriatric section says the trials did not include enough women over 65 to determine whether responses differ. That is an evidence limitation, not a rule that age alone selects or excludes the medicine.
A useful ongoing conversation separates the symptom benefit from tolerability, test results and access. Ask how these will be reviewed together and how another treating clinician will receive relevant information. The product record supports an informed assessment; it cannot certify that a particular online offer provides that assessment or predict the result for the person reading this page.
Follow the evidence
Source documents
Read each source for the product, population and purpose it describes. Commercial pages document advertised terms, not individual care outcomes.
- Veozah (fezolinetant) US prescribing informationExact official DailyMed label. Revised February 2026; boxed hepatotoxicity warning; same-day official HTML record reviewed with original timestamp · Checked 2026-09-29